{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:53:15Z","timestamp":1785451995214,"version":"3.56.0"},"reference-count":30,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2023,6,12]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>As the population ages and treatment options for heart valve disease increase, the number of patients with intracardiac valve prostheses is growing rapidly. Although all devices have the potential to cause thrombus formation, the propensity depends on the type of prosthesis as well as risk of the individual patient. Mechanical valve prostheses carry the highest (and persistent) risk of thromboembolism, and these patients require anticoagulation with vitamin K antagonists (warfarin). Required international normalised ratio levels are dependent on the location of the valve (mitral&gt;aortic), type of valve (ball and cage vs bilealfet vs On-X bilealfet) and rhythm. The risk of tissue (biological) prosthesis is highest soon after surgery and is dependent on individual patient risk including age, valve location (mitral&gt;aortic), history of thromboembolic events and rhythm. In patients with no other indication for anticoagulation, there is uncertainty on the benefits of anticoagulation versus antiplatelet therapy in patients with tissue prostheses or repaired native valves. Patients with an a priori indication for anticoagulation with a direct oral anticoagulant can continue taking this class of drug. Patients with transcatheter aortic valve implantation devices and no additional evidence-based indication for dual antiplatelet therapy or anticoagulation can be maintained on aspirin monotherapy. Patients undergoing transcatheter instrumentation in the mitral valve position should be anticoagulated, although there is currently no published evidence for antithrombotic management in this group of patients. Patients with thrombosed devices (commonly mitral mechanical) should preferably be treated surgically. Patients at high risk of thromboembolism (with mechanical prostheses) should undergo bridging therapy when undergoing surgery.<\/jats:p>","DOI":"10.1136\/heartjnl-2022-321387","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T13:20:10Z","timestamp":1689168010000},"page":"87-93","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Antithrombotic therapy after heart valve intervention: review of mechanisms, evidence and current guidance"],"prefix":"10.1136","volume":"110","author":[{"given":"Ann","family":"Cheng","sequence":"first","affiliation":[{"name":"Infection Immunity and cardiovascular Disease, The University of Sheffield, Sheffield, UK"},{"name":"Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Malkin","sequence":"additional","affiliation":[{"name":"Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-6131","authenticated-orcid":false,"given":"Norman Paul","family":"Briffa","sequence":"additional","affiliation":[{"name":"Infection Immunity and cardiovascular Disease, The University of Sheffield, Sheffield, UK"},{"name":"Cardiothoracic Surgery, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"2025092102341846000_110.2.87.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507063330103"},{"key":"2025092102341846000_110.2.87.2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.1.53"},{"key":"2025092102341846000_110.2.87.3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.94.9.2107"},{"key":"2025092102341846000_110.2.87.4","doi-asserted-by":"publisher","DOI":"10.1510\/icvts.2007.152819"},{"key":"2025092102341846000_110.2.87.5","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2002.121162"},{"key":"2025092102341846000_110.2.87.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61294-4"},{"key":"2025092102341846000_110.2.87.7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/HCO.0000000000000149","article-title":"Reduced anticoagulation is safe in high-risk patients with the On-X mechanical aortic valve","volume":"30","author":"Yanagawa","year":"2015","journal-title":"Curr Opin Cardiol"},{"key":"2025092102341846000_110.2.87.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.05.005"},{"key":"2025092102341846000_110.2.87.9","article-title":"Antiplatelet and anticoagulation for patients with prosthetic heart valves","volume":"2013","author":"Massel","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025092102341846000_110.2.87.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300615"},{"key":"2025092102341846000_110.2.87.11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ahj.2020.06.014","article-title":"Rationale and design of PROACT Xa: a randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of Apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve","volume":"227","author":"Jawitz","year":"2020","journal-title":"Am Heart J"},{"key":"2025092102341846000_110.2.87.12","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1161\/CIRCULATIONAHA.118.035612","article-title":"Non\u2013vitamin K antagonist oral anticoagulants for mechanical heart valves","volume":"138","author":"Aimo","year":"2018","journal-title":"Circulation"},{"key":"2025092102341846000_110.2.87.13","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.10.1083"},{"key":"2025092102341846000_110.2.87.14","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)00563-6"},{"key":"2025092102341846000_110.2.87.15","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivu392"},{"key":"2025092102341846000_110.2.87.16","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivs102"},{"key":"2025092102341846000_110.2.87.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2016.11.021"},{"key":"2025092102341846000_110.2.87.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.05.029"},{"key":"2025092102341846000_110.2.87.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.06.014"},{"key":"2025092102341846000_110.2.87.20","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.clinthera.2019.10.008","article-title":"Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves","volume":"41","author":"Russo","year":"2019","journal-title":"Clin Ther"},{"key":"2025092102341846000_110.2.87.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101897"},{"key":"2025092102341846000_110.2.87.22","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-018-1735-x","article-title":"Correction to: antithrombotic therapy after mitral valve repair: VKA or aspirin?","volume":"46","author":"van der Wall","year":"2018","journal-title":"J Thromb Thrombolysis"},{"key":"2025092102341846000_110.2.87.23","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1001\/jama.2022.5776","article-title":"Effect of transcatheter aortic valve implantation vs surgical aortic valve replacement on all-cause mortality in patients with aortic stenosis: a randomized clinical trial","volume":"327","author":"Investigators","year":"2022","journal-title":"JAMA"},{"key":"2025092102341846000_110.2.87.24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.amjcard.2020.07.018","article-title":"Meta-analysis of incidence, predictors and consequences of clinical and Subclinical Bioprosthetic leaflet thrombosis after Transcatheter aortic valve implantation","volume":"132","author":"Sannino","year":"2020","journal-title":"Am J Cardiol"},{"key":"2025092102341846000_110.2.87.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814052"},{"key":"2025092102341846000_110.2.87.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816885"},{"key":"2025092102341846000_110.2.87.27","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000923"},{"key":"2025092102341846000_110.2.87.28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"ESC\/EACTS guidelines for the management of valvular heart diseaseDeveloped by the task force for the management of valvular heart disease of the European society of cardiology (ESC) and the European Association for Cardio-Thoracic surgery (EACTS)","volume":"43","author":"Vahanian","year":"2021","journal-title":"Eur Heart J"},{"key":"2025092102341846000_110.2.87.29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008425","article-title":"Thirty-day outcomes of Transcatheter mitral valve replacement for degenerated mitral Bioprostheses (valve-in-valve), failed surgical rings (valve-in-ring), and native valve with severe mitral annular calcification (valve-in-mitral Annular calcification) in the United States: data from the Society of Thoracic Surgeons\/American College of Cardiology\/Transcatheter Valve Therapy Registry","volume":"13","author":"Guerrero","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"2025092102341846000_110.2.87.30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.856120"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2022-321387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T09:34:28Z","timestamp":1758447268000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2022-321387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,20]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/heartjnl-2022-321387"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2022-321387","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]}}}